Reduction in Artemisia Pollen-Specific IgE Levels During House Dust Mite Allergen Immunotherapy in Polysensitized Allergic Rhinitis Patients: A Three-Year Retrospective Study in Northern, China.

IF 3 3区 医学 Q2 ALLERGY
Journal of Asthma and Allergy Pub Date : 2025-04-29 eCollection Date: 2025-01-01 DOI:10.2147/JAA.S525620
Xiaowei Sun, Xu Li, Tingting Gao, Peize Liu, Na Liu, Peng Jin, Lili Zhi
{"title":"Reduction in Artemisia Pollen-Specific IgE Levels During House Dust Mite Allergen Immunotherapy in Polysensitized Allergic Rhinitis Patients: A Three-Year Retrospective Study in Northern, China.","authors":"Xiaowei Sun, Xu Li, Tingting Gao, Peize Liu, Na Liu, Peng Jin, Lili Zhi","doi":"10.2147/JAA.S525620","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong> Allergen immunotherapy (AIT) is a well-established treatment for allergic diseases, particularly in patients with allergic rhinitis and asthma. In regions where patients are polysensitized, AIT can have broader immunomodulatory effects. This study investigates the impact of house dust mite AIT on IgE responses to both dust mites and non-target allergens, specifically Artemisia pollen, in polysensitized allergic rhinitis patients.</p><p><strong>Methods: </strong> This retrospective study included polysensitized patients aged 18 or older with a diagnosis of allergic rhinitis or rhinitis with asthma and positive IgE for both house dust mites and Artemisia pollen. Patients who completed at least three years of AIT for house dust mites were included. IgE levels for <i>Dermatophagoides pteronyssinus</i> (Der p), <i>Dermatophagoides farinae</i> (Der f), and Artemisia pollen were measured at baseline and after 1, 2, and 3 years of treatment. Clinical outcomes were also recorded, including Total Nasal Symptom Score (TNSS), Visual Analog Scale (VAS), and medication use.</p><p><strong>Results: </strong> Over three years, SIgE levels for Der p significantly decreased (p = 0.0001), while Der f showed a slight and significant decrease (p = 0.0334). Artemisia pollen-specific IgE decreased modestly (p = 0.0478), despite not being the target allergen. Total IgE levels increased slightly without statistical significance (p = 0.9026). Clinical outcomes improved significantly, with reductions in TNSS, VAS, and medication scores (all p < 0.0001), alongside a decrease in eosinophil counts, reflecting clinical and immunological benefits.</p><p><strong>Conclusion: </strong> House dust mite AIT not only reduces dust mite-specific IgE levels but also leads to unexpected reductions in IgE levels for non-target allergens, such as Artemisia pollen. This suggests that AIT has broader immunological benefits, improving overall tolerance to multiple allergens in polysensitized patients.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"665-673"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12050207/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma and Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JAA.S525620","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background:  Allergen immunotherapy (AIT) is a well-established treatment for allergic diseases, particularly in patients with allergic rhinitis and asthma. In regions where patients are polysensitized, AIT can have broader immunomodulatory effects. This study investigates the impact of house dust mite AIT on IgE responses to both dust mites and non-target allergens, specifically Artemisia pollen, in polysensitized allergic rhinitis patients.

Methods:  This retrospective study included polysensitized patients aged 18 or older with a diagnosis of allergic rhinitis or rhinitis with asthma and positive IgE for both house dust mites and Artemisia pollen. Patients who completed at least three years of AIT for house dust mites were included. IgE levels for Dermatophagoides pteronyssinus (Der p), Dermatophagoides farinae (Der f), and Artemisia pollen were measured at baseline and after 1, 2, and 3 years of treatment. Clinical outcomes were also recorded, including Total Nasal Symptom Score (TNSS), Visual Analog Scale (VAS), and medication use.

Results:  Over three years, SIgE levels for Der p significantly decreased (p = 0.0001), while Der f showed a slight and significant decrease (p = 0.0334). Artemisia pollen-specific IgE decreased modestly (p = 0.0478), despite not being the target allergen. Total IgE levels increased slightly without statistical significance (p = 0.9026). Clinical outcomes improved significantly, with reductions in TNSS, VAS, and medication scores (all p < 0.0001), alongside a decrease in eosinophil counts, reflecting clinical and immunological benefits.

Conclusion:  House dust mite AIT not only reduces dust mite-specific IgE levels but also leads to unexpected reductions in IgE levels for non-target allergens, such as Artemisia pollen. This suggests that AIT has broader immunological benefits, improving overall tolerance to multiple allergens in polysensitized patients.

Abstract Image

Abstract Image

多致敏性变应性鼻炎患者屋尘螨过敏原免疫治疗期间青蒿花粉特异性IgE水平的降低:中国北方一项为期三年的回顾性研究
背景:过敏原免疫疗法(AIT)是一种公认的治疗过敏性疾病的方法,特别是对变应性鼻炎和哮喘患者。在患者多致敏的地区,AIT可具有更广泛的免疫调节作用。本研究探讨了房尘螨对多致敏性变应性鼻炎患者对尘螨和非靶过敏原(特别是青蒿花粉)的IgE反应的影响。方法:本回顾性研究纳入了年龄在18岁及以上、诊断为变应性鼻炎或鼻炎合并哮喘、屋尘螨和青蒿花粉IgE均阳性的多致敏患者。患者完成了至少三年的房内尘螨的AIT包括在内。在基线和治疗1年、2年和3年后,测量了翼状棘球蚴(derp)、粉状棘球蚴(derf)和青蒿花粉的IgE水平。同时记录临床结果,包括总鼻症状评分(TNSS)、视觉模拟评分(VAS)和药物使用情况。结果:三年内,Der p的SIgE水平显著降低(p = 0.0001), Der f略有显著降低(p = 0.0334)。尽管不是目标过敏原,但青蒿花粉特异性IgE略有下降(p = 0.0478)。总IgE水平略有升高,但无统计学意义(p = 0.9026)。临床结果显著改善,TNSS、VAS和用药评分下降(均p < 0.0001),同时嗜酸性粒细胞计数下降,反映了临床和免疫方面的益处。结论:屋尘螨AIT不仅降低了尘螨特异性IgE水平,而且导致非靶向过敏原(如青蒿花粉)的IgE水平意外降低。这表明AIT具有更广泛的免疫益处,可提高多致敏患者对多种过敏原的总体耐受性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Asthma and Allergy
Journal of Asthma and Allergy Medicine-Immunology and Allergy
CiteScore
5.30
自引率
6.20%
发文量
185
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physiology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies. Although the main focus of the journal will be to publish research and clinical results in humans, preclinical, animal and in vitro studies will be published where they shed light on disease processes and potential new therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信